Videos

What’s On the Horizon for Small Cell Lung Cancer Research?

March 6th 2025, 8:00pm

Video

On the heels of two FDA approvals in lung cancer treatments, what innovations are next?

A Patient’s Journey With Colon Cancer and Her Advocacy Mission

March 6th 2025, 5:34pm

Video

Melissa Ursini, diagnosed with stage 2 colon cancer, shares her journey to raise awareness and encourage early detection through colonoscopies.

Colostomies and Colon Cancer, a Lifesaving Choice, Not a Last Resort

March 5th 2025, 5:00pm

Video

Dr. Andreas M. Kaiser explains how a colostomy may preserve a patient’s health and help to avoid colorectal cancer complications.

Better Understanding Genetic Mutations Influence in Cancer Care

March 4th 2025, 8:02pm

Video

Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.

Expert Explains Safety of Krazati Regimen For Treating Colorectal Cancer

March 3rd 2025, 10:00pm

Video

Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and less immune suppression.

Breaking Down The Results of The ALPHA/ALPHA2 Study in Large B-Cell Lymphoma

March 1st 2025, 7:00pm

Video

Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.

An Expert Highlights His Key Takeaways From The 2025 ASCO GU Symposium

February 28th 2025, 5:00pm

Video

Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.

Off-The-Shelf CAR T Therapy Elicits Responses in Large B-Cell Lymphoma

February 26th 2025, 10:00pm

Video

Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.

A Study Investigates If CAR T Therapy Directly Causes Secondary Malignancies

February 26th 2025, 8:00pm

Video

There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.

Minimal Residual Disease Testing’s Variability Across Cancer Types

February 26th 2025, 5:00pm

Video

Dr. Christopher R. Flowers explains that MRD testing varies by cancer type, with results impacting recurrence risk and monitoring based on disease characteristics.